FIG 1.

CONSORT diagram. A total of 198 anaplastic lymphoma kinase (ALK)-positive patients in expansion cohorts EXP2 to EXP5 were treated. Of these, 59 had received prior crizotinib and 139 had received one or more second-generation inhibitors, often in addition to crizotinib. The numbers of patients with cell-free DNA (cfDNA) and tissue samples are shown. De novo tissue refers to a biopsy obtained within 28 days of starting lorlatinib. EXP2, prior crizotinib only; EXP3A, prior crizotinib and chemotherapy; EXP3B, one prior non-crizotinib ALK tyrosine kinase inhibitor (TKI) with or without chemotherapy; EXP4, two prior ALK TKIs with or without chemotherapy; EXP5, three prior ALK TKIs with or without chemotherapy.